160 related articles for article (PubMed ID: 36652664)
21. Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients.
Hylebos M; Op de Beeck K; Pauwels P; Zwaenepoel K; van Meerbeeck JP; Van Camp G
Lung Cancer; 2018 Oct; 124():19-22. PubMed ID: 30268460
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive DNA methylation analysis of tissue of origin of plasma cell-free DNA by methylated CpG tandem amplification and sequencing (MCTA-Seq).
Liu X; Ren J; Luo N; Guo H; Zheng Y; Li J; Tang F; Wen L; Peng J
Clin Epigenetics; 2019 Jun; 11(1):93. PubMed ID: 31234922
[TBL] [Abstract][Full Text] [Related]
23. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
[TBL] [Abstract][Full Text] [Related]
24. Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups.
Gallego S; Chi YY; De Salvo GL; Li M; Merks JHM; Rodeberg DA; van Scheltinga ST; Mascarenhas L; Orbach D; Jenney M; Million L; Minard-Colin V; Wolden S; Zanetti I; Parham DM; Mandeville H; Venkatramani R; Bisogno G; Hawkins DS;
Pediatr Blood Cancer; 2021 Mar; 68(3):e28832. PubMed ID: 33245207
[TBL] [Abstract][Full Text] [Related]
25. Hypermethylated
van Zogchel LMJ; van Wezel EM; van Wijk J; Stutterheim J; Bruins WSC; Zappeij-Kannegieter L; Slager TJE; Schumacher-Kuckelkorn R; Verly IRN; van der Schoot CE; Tytgat GAM
JCO Precis Oncol; 2020; 4():. PubMed ID: 32923888
[TBL] [Abstract][Full Text] [Related]
26. Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia.
Wong IH; Chan J; Wong J; Tam PK
Clin Cancer Res; 2004 Feb; 10(3):994-1002. PubMed ID: 14871978
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Role of RASSF1A, SOX17 and Wif-1 Promoter Methylation Status in Cell-Free DNA of Advanced Gastric Cancer Patients.
Karamitrousis EI; Balgkouranidou I; Xenidis N; Amarantidis K; Biziota E; Koukaki T; Trypsianis G; Karayiannakis A; Bolanaki H; Kolios G; Lianidou E; Kakolyris S
Technol Cancer Res Treat; 2021; 20():1533033820973279. PubMed ID: 33928818
[TBL] [Abstract][Full Text] [Related]
28. Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.
van 't Erve I; Medina JE; Leal A; Papp E; Phallen J; Adleff V; Chiao EJ; Arun AS; Bolhuis K; Simmons JK; Karandikar A; Valkenburg KC; Sausen M; Angiuoli SV; Scharpf RB; Punt CJA; Meijer GA; Velculescu VE; Fijneman RJA
Clin Cancer Res; 2023 Mar; 29(5):899-909. PubMed ID: 36534496
[TBL] [Abstract][Full Text] [Related]
29. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction.
Lee JS; Kim M; Seong MW; Kim HS; Lee YK; Kang HJ
Clin Chem Lab Med; 2020 Mar; 58(4):527-532. PubMed ID: 31874093
[TBL] [Abstract][Full Text] [Related]
30. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
[TBL] [Abstract][Full Text] [Related]
31. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Ichou FA; den Ouden E; Versteeg R; Caron HN; Tytgat GA; van der Schoot CE
Clin Cancer Res; 2012 Feb; 18(3):808-14. PubMed ID: 22142825
[TBL] [Abstract][Full Text] [Related]
32. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
[TBL] [Abstract][Full Text] [Related]
33. Computational challenges in detection of cancer using cell-free DNA methylation.
Sharma M; Verma RK; Kumar S; Kumar V
Comput Struct Biotechnol J; 2022; 20():26-39. PubMed ID: 34976309
[TBL] [Abstract][Full Text] [Related]
34. Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
Ørntoft MW; Jensen SØ; Øgaard N; Henriksen TV; Ferm L; Christensen IJ; Reinert T; Larsen OH; Nielsen HJ; Andersen CL
Int J Cancer; 2021 Apr; 148(7):1665-1675. PubMed ID: 33320961
[TBL] [Abstract][Full Text] [Related]
35. Detection and utility of cell-free and circulating tumour DNA in bone and soft-tissue sarcomas.
Tsoi KM; Gokgoz N; Darville-O'Quinn P; Prochazka P; Malekoltojari A; Griffin AM; Ferguson PC; Wunder JS; Andrulis IL
Bone Joint Res; 2021 Sep; 10(9):602-610. PubMed ID: 34558310
[TBL] [Abstract][Full Text] [Related]
36. Associations between tumor mutations in cfDNA and survival in non-small cell lung cancer.
Ottestad AL; Dai HY; Halvorsen TO; Emdal EF; Wahl SGF; Grønberg BH
Cancer Treat Res Commun; 2021; 29():100471. PubMed ID: 34607221
[TBL] [Abstract][Full Text] [Related]
37. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR-TKI treatment in advanced non-small cell lung cancer.
Zheng J; Wang Y; Hu C; Zhu M; Ii J; Lin C; Lu C; Dou Y; Zhao C; Zhang Y; Wu D; Li L; Tang H; He T; Pan C; Han R; He Y
Thorac Cancer; 2022 Nov; 13(22):3162-3173. PubMed ID: 36193794
[TBL] [Abstract][Full Text] [Related]
39. Metastatic rhabdomyosarcoma with exclusive distant lymph node involvement: A European Pediatric Soft tissue sarcoma Study Group (EpSSG) report.
Mercolini F; Merks JHM; Minard-Colin V; Cameron A; van Scheltinga SEJT; Sher O; Fichera G; Orbach D; Glosli H; Coppadoro B; Gallego S; Chisholm JC; Bisogno G
Pediatr Blood Cancer; 2023 Mar; 70(3):e30143. PubMed ID: 36519598
[TBL] [Abstract][Full Text] [Related]
40. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
